/
NAMS
$33.87+$0.63 (+1.90%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.9B
117M shares
52-week range
$17.97 – $42.21
66% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.43%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$23.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $102.7M | $14.1M | $45.6M | $22.5M |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $59.0K |
| Gross profit | $0 | $0 | $102.7M | $14.1M | $45.6M | $22.4M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 99.7% |
| R&D | $4.9M | $29.0M | $86.7M | $159.4M | $151.4M | $141.8M |
| Operating income | −$6.6M | −$35.0M | −$3.6M | −$183.0M | −$176.3M | −$225.7M |
| EBITDA | −$6.6M | −$41.4M | −$22.3M | −$176.9M | −$241.5M | −$242.3M |
| Net income | −$7.0M | −$41.8M | −$22.6M | −$176.9M | −$241.6M | −$203.8M |
| Net margin | — | — | -22.0% | -1255.8% | -530.3% | -905.7% |
| EPS (diluted) | -1.15 | -3.34 | -1.19 | -2.15 | -2.56 | -1.75 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $29M | $-1.81 | $-1.96–$-1.62 | 10 |
| 2027 | $171M | $-1.39 | $-6.83–$6.32 | 8 |
| 2028 | $423M | $-0.27 | $-3.30–$6.08 | 9 |
| 2029 | $796M | $1.51 | $-0.21–$5.41 | 3 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.51
Price
$33.87
Implied downside
-90%
Peer comparison
NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
www.newamsterdampharma.com- Employees
- 100
- IPO / List date
- Nov 23, 2022
- HQ
- NARRDEN, P7
Held by traders on TradeandTell
No one on the platform currently holds NAMS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NAMS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NAMS yet.
